Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

WIPO Re:Search bridges public, private sectors for neglected disease research (IP Watch) (WIPO) (IPKat) (IP Watch) (Patent Docs)

Section 3(d) equivalent in the offing for Thailand…(Spicy IP)

Australia: FCAFC upholds claim by Alphapharm that claims 1 to 17 and 27 of Wyeth’s Venlafaxine patent are invalid (IP Whiteboard)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

WIPO Re:Search bridges public, private sectors for neglected disease research (IP Watch) (WIPO) (IPKat) (IP Watch) (Patent Docs)

WTO TRIPS Council: Ecuador questions the European Union on Italian compulsory licenses (KEI)

KEI notes from the Ninth Round of TPPA negotiations (KEI)

Brazil’s intervention at Special Session of the Executive Board on WHO Reform (KEI)

WTO TRIPS Council: Canada’s intervention on Access to Medicines in context of Paragraph 6 and Bill C-393 (KEI)

Plagues, Pandemics and patents: Legality and morality[1] and even movies[2] (IP Osgoode)

Featured resource: National Center for Biotechnology Information (Patent Quality Matters)

Nanotech roundup: foods v. drugs, the EC definition, and NNI’s EHS research strategy (FDA Law Blog)

Brazil: Pharmaceutical market moves serious $ (IP tango)

EU: Brüstle: what will happen next? (IPKat)

EU: CJEU ruling on exhaustion in Community plant variety rights case: Greenstar-Kanzi Europe NV v Jean Hustin, Jo Goossens (IPKat)

EU: Revised EPO patent for conventional broccoli has public interest ramifications (IP Watch)

EU: EPO Enlarged Board of Appeal decides on disclaimers for disclosed embodiments: G 0002/10 (Disclaimer/SCRIPPS) (IPEG)

EU: Medeva and Georgetown rulings: save the date! (The SPC Blog)

EU: Medeva and the role of the Advocate General: a call for more communication (The SPC Blog)

Nigeria: Tackling counterfeits – Pins on pills! (Afro-IP)

Thailand: Section 3(d) equivalent in the offing for Thailand…(Spicy IP)

US: Commercialization and job creation in the biotechnology sector (BIOtechNOW)

US: Can biotechnology help curb the deficit crisis? (Patent Baristas)

US: Life Sciences venture funding drops in third quarter (Patent Docs)

USPTO announces agenda for next BCP Customer Partnership Meeting (Patent Docs)

US: Mayo v. Prometheus: the patentee’s section 101 argument (Patently-O)

US: CAFC Permits post-filing date unexpected results to support non-obviousness: Genetics Institute v. Novartis Vaccines & Diagnostics (Pharma Patents)

US: CAFC Affirms district court de novo review in section 146 action: Streck v. Research & Diagnostic Systems (Pharma Patents)

US: Roundup Ready® Soybeans: Patent exhaustion in self-replicating biotechnologies (IP Osgoode)

US: FDA continues efforts to expand power over intrastate commerce (FDA Law Blog)

US: Defendants’ persistence in pursuing “baseless inequitable conduct claim” justified award of attorneys’ fees to plaintiff: Pfizer et. al v. Teva Pharmaceuticals USA et al (Docket Report)

US: Fred Hutchinson Cancer Research Center files patent infringement complaint against Branhaven over sales of Canine Heritage XL Breed Test (Patent Docs)

 

Products

Atelvia (Risedronate sodium delayed-release) – US: Warner Chilcott files patent infringement complaint against Watson in response to Para IV certification (Patent Docs)

Butrans (Buprenorphine) – US: PTO says PTE not available in “reverse Photocure” case (FDA Law Blog)

Cipro (Ciprofloxacin) – US: California Court of Appeal affirms superior court decision that Cipro patent settlement agreements do not violate state antitrust laws (FDA Law Blog)

Cyclen Lo (Norgestimate and Ethinyl estradiol) – US: Janssen files patent infringement complaint against Sun Pharma in response to Para IV certification filing (Patent Docs)

Daytrana (Methylphenidate) – US: Noven files patent infringement complaint against Watson in response to Para IV certification filing (Patent Docs)

Efexor (Venlafaxine) – Australia: FCAFC upholds claim by Alphapharm that claims 1 to 17 and 27 of Wyeth’s Venlafaxine patent are invalid (IP Whiteboard)

Escitalopram – Austria: SPC granted for an enantiomer (escitalopram) cannot be declared void because a prior SPC was granted for the racemate (citalopram) when both protected by individual patents and thus are different products (Kluwer Patent Blog)

Luvox CR (Fluvoxamine maleate) – US: Alkermes Pharma Ireland files patent infringement complaint against Torrent in response to Para IV certification filing (Patent Docs)

Nasacort (Triamcinolone) – US: TTAB turns up nose at NASACORT opposition to LAZACOR for rhinitis remedies (TTABlog)

Patanase (Olopatadine hydrochloride) – US: Alcon files patent infringement complaint against Perrigo in response to Para IV certification (Patent Docs)

Prandin (Repaglinide) – US: Novo Nordisk files patent infringement complaint against Sandoz in response to Para IV certification filing (Patent Docs)

Temodar (Temozolomide) – US: Cert denied in Merck/Teva case (IPBiz)

Valsartan – France: Does SPC for drug A prevent the marketing of drug A+B? French courts give conflicting answers in preliminary injunction proceedings: Actavis v Novartis (EPLAW)

Vytorin (Ezetimibe and Simvastatin) – US: Schering  files patent infringement complaint against Actavis in response to Para IV certification (Patent Docs)